Amgen Inc. $AMGN Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 2.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 115,190 shares of the medical research company’s stock after selling 2,298 shares during the quarter. Great Lakes Advisors LLC’s holdings in Amgen were worth $32,507,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in AMGN. Vanguard Group Inc. raised its stake in shares of Amgen by 1.6% in the second quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock worth $14,996,807,000 after purchasing an additional 841,117 shares during the last quarter. State Street Corp boosted its holdings in Amgen by 0.6% in the second quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after purchasing an additional 177,035 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Amgen by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock valued at $3,619,489,000 after buying an additional 291,271 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Amgen by 5.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after buying an additional 687,735 shares during the period. Finally, Laurel Wealth Advisors LLC boosted its stake in shares of Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after buying an additional 6,676,575 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ AMGN opened at $342.22 on Thursday. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The stock’s 50 day simple moving average is $332.38 and its 200-day simple moving average is $308.67. The company has a market cap of $184.28 billion, a PE ratio of 26.45, a price-to-earnings-growth ratio of 3.11 and a beta of 0.45. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $353.25.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm’s revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the company earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Analyst Ratings Changes

AMGN has been the subject of several recent research reports. Royal Bank Of Canada lifted their price target on Amgen from $330.00 to $335.00 and gave the company an “outperform” rating in a research report on Thursday, January 8th. HSBC reiterated a “buy” rating and issued a $425.00 target price on shares of Amgen in a research note on Wednesday, December 10th. Daiwa Capital Markets raised their price target on shares of Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. BMO Capital Markets raised their target price on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Finally, UBS Group increased their price target on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average target price of $339.71.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.